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groups. The GLM-based estimate of the increase in post-event costs over 30 days
among patients with evidence of any adverse events was $9,807 (95% CI: $4,386-
$22,947). For all types of adverse events examined, the estimated difference in costs
between evented andnon-evented patientswas positive; the 95%CI did not include
zero for all of the adverse events considered except hypertension and proteinurea.
CONCLUSIONS: Costs associated with AEs of first-line targeted therapies are sub-
stantial in patients with mRCC. Efforts to prevent and/or better manage these
events may reduce overall healthcare costs.
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OBJECTIVES: To describe patient characteristics and evaluate inpatient utilization
and costs among patients with lung cancer in Tianjin, China. METHODS: Retro-
spective analyses were conducted using Urban Employee Basic Medical Insurance
(UEBMI) claims database from Tianjin from 2003 to 2007, which included a 30%
random sample of UEBMI enrollees in Tianjin. Patients with 1 lung cancer di-
agnosis and continuous eligibility 6 months before and 12 months after the first
diagnosis were selected. Inpatient utilization and costs during the 12-month study
period were estimated. Costs were valued in 2007 US dollars using the correspond-
ing inflation rate and exchange rate. RESULTS: A total of 2351 lung cancer patients
were included with mean age of 66.5 years, 34.9% female, and 86.9% retired. Ap-
proximately 50.0% patients had metastasis at the first diagnosis. Among them,
46.9% had cardiovascular disease, 27.6% had COPD, and 23.3% had hypertension.
The mean number of admissions was 2.44 during the 12 months, with 53.3% of
patients having 1 admission. About 84.8% hospitalizations occurred in a tier-3
hospital. Themean length of stay was 25.9 and 24.2 days, respectively, for first and
subsequent admissions. Anti-neoplastic agents were used in 66.1% hospitaliza-
tions. The mean cost per hospitalization was $2473 and $ 2260 for first and subse-
quent admissions, respectively. The total 12-month inpatient costs were $ 5511 per
patient: 70.9% were covered by payers and the rest by patients. Approximately
58.2% of the total inpatients costs were attributed to medication costs. Examina-
tions,medical consumables and bed accounted for 13.4%, 6.3% and 5.0% of the total
inpatient costs, respectively. CONCLUSIONS: The majority of lung cancer patients
is metastatic and treated in tier-3 hospitals. Lung cancer poses substantial eco-
nomic burden to payers and patients. The majority of the costs were attributed to
medications.
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OBJECTIVES: China has over 50% of new hepatocellular carcinoma (HCC) cases in
the world. The study estimated the economic burden associated with HCC in Tian-
jin, China.METHODS: Data were obtained from the Tianjin Urban Employee Basic
Medical Insurance (UEBMI) database (2003-2007), including inpatient claims for
medical services and prescription drugs for 30% enrollees. Adult patients with  1
diagnosis of HCC and 6-month continuous enrollment before and after the first
HCC diagnosis between 2003 and 2007 were selected. Patient characteristics,
healthcare utilization and costs were analyzed. Costs were estimated in 2007 U.S.
dollars using the Medical Service Consumer Price Index (CPI) in China and an
exchange rate of 7.598 Chinese Yuan to 1 USD in 2007. RESULTS: A total of 857 HCC
eligible patients were included in the analysis with amean age of 62.2 years, 25.0%
female and 72.4% retired. Approximately 65.2% of all patients had 1 comorbidity,
48.4% had cirrhosis, 35.4% had HBV/HCV, 18.1% had esophageal varices, 10.2% had
encephalopathy, and 14.4% had diabetes mellitus. The mean number of hospital-
izations during the 6-month study period was 1.62, with 40.0% patients having 1
hospital admissions. About 84.0% hospitalizations occurred in tier-3 hospitals. The
mean length of stay (LOS) was 24.6 days per hospitalization and 38.9 days during
the 6-month study period. The total 6-month inpatient costs were $4,400 per pa-
tient with 70.1% covered by UEBMI and 29.9% by patients. Medication costs ac-
counted for 56.3% of total inpatient costs; the rest was attributed to medical ser-
vices. Examinations,medical consumables and bed costs accounted for 14.3%, 9.3%
and 4.9% of total inpatient costs, respectively. CONCLUSIONS: The majority of
Chinese HCC patients receive treatment in tier-3 hospitals. HCC poses substantial
economic burden to the payer and patients in China. Medications accounts for
more than half of the total inpatient costs.
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OBJECTIVES: Chemotherapy-induced nausea and vomiting (CINV) is a major ad-
verse effect of cancer treatment. The 5-hydroxytryptamine3 receptor antagonists
(5-HT3-RA), a class of antiemetic medications, are indicated for the prevention of
CINV. This study compared treatment costs of patients with and without CINV
following a highly or moderately emetogenic chemotherapy regimen and anti-
emetic prevention with a 5-HT3-RA. METHODS: This study was a retrospective
cohort analysis using the MarketScan® Medicaid database. Continuously enrolled
adult patients, newly diagnosed with cancer, newly treated with a MEC or HEC
regimen, who received a prophylactic 5-HT3-RA during the January 1, 2005 to De-
cember 31, 2009, were identified. The primary outcome of interest was the overall
cost of care for patients with and without CINV. CINV was defined by any claim for
nausea and vomiting, fluid depletion or replacement, and the use of a rescue anti-
emetic during a cycle of chemotherapy. RESULTS: A total of 8812 patients were
identified, 33%undergoingHEC and 67% treatedwith aMEC regimen. Themean age
was 56.7 and 65%were female. Patients were treated with a total of 43,418 cycles of
chemotherapy. The overall rate of CINV was 17% per cycle and the rate differed by
prophylactic 5-HT3-RA utilized. The rate of CINV per cycle for patients treated with
palonosetron was 13% compared to 20% for those treated with another 5-HT3-RA.
The average total paid health care cost per cycle was $2827. Average cost per cycle
with and without CINV was $3839 and $2695, respectively, p0.001.
CONCLUSIONS: In this retrospective study, health care costs associated with the
prevention of CINV were approximately $1144 per cycle of chemotherapy. This
suggests that a reduction in the rate of CINV for patients undergoing chemotherapy
could result in significant health care cost savings in the Medicaid system. Further
studies are warranted to confirm these findings.
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OBJECTIVES: Melanoma is the most serious type of skin cancer that starts in me-
lanocytes. New treatment methods may offer significant benefits in treating pa-
tients with advanced melanoma, but in order to assess their cost-effectiveness via
pharmacoeconomic modelling data on epidemiology, current standard of care,
adverse events and costs is needed. The aim of this study is to collect such infor-
mation using surveys in major centers in Poland.METHODS: A questionnaire was
designed and implemented in MS Excel, and then distributed in three hospitals in
Poland covering the majority of melanoma patients being treated. The survey
questions encompassed: the disease characteristics, current treatment patterns,
health care resources utilization and costs among patients diagnosed with mela-
noma (SIII-SIV). Resources costs and standard of care data for melanoma patients
were divided into three therapy lines, and information such as treatment scheme,
drug cost and performed diagnostic procedures were collected. RESULTS: The pre-
liminary results coming from one center are available at this stage. Melanoma
incidence andmortality rate (per 100,000) are equal respectively to 8.8 and 3.7 (data
for year 2010). The continuation of existing trends will cause an increase of mor-
bidity in the next years and the numer of incidence cases can even double in 10
years time. The most common form of treatment in metastatic patients is chemo-
therapy. The results demonstrate that costs of consecutive lines of therapy de-
crease, and total yearly cost of 1st, 2nd and 3rd line treatment is estimated to be
1.2mln PLN (1 Euro4.4 PLN). Adverse events total cost amounts to 77,000 PLN.
CONCLUSIONS:Melanoma is one of the most malignant human cancers in Poland
with an increasing incidence rate. In connection with several treatment patterns
that exist, it is necessary to gather detailed clinical data in order to use it in phar-
macoeconomic modelling in health technology assessment process.
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OBJECTIVES: To assess the clinical and economic burden of ovarian cancer in the
US veteran population.METHODS: A retrospective study (October 01, 2005 to Sep-
tember 30, 2010) was conducted using the Veterans Health Affairs Medical SAS
Datasets. Patients diagnosed with ovarian cancer were included in the study.
Health care resource utilization and costs were assessed for ovarian cancer pa-
tients in the 12-month follow-up period. Patients’ demographic, clinical and dis-
charge statuses were compared using Chi-square testing and standardized differ-
ences. Student t-tests were used for the means of continuous variables. Mortality
and survival rateswere also calculated using the Kaplan andMeiermethod and the
PROC LIFETEST procedure. RESULTS: Among the selected ovarian cancer patients
(n1,148), the total mortality rate in the 12-month follow-up period was 20.84%
(n239). The most commonly prescribed medications were sodium chloride
(3.14%), dextrose (1.83%), potassium chloride (1.58%), and warfarin (1.02%). The
average number of inpatient (0.46), emergency room (ER) (0.41), physician office
(30.31) and outpatient visits (30.74) were calculated per patient. The percentage of
inpatient, ER, physician office and outpatient were 27.35%, 21.43%, 100% and 100%,
respectively. The cost of inpatient, ER, physician office and outpatient visits were
$6610, $138, $9702, and $9959, respectively. CONCLUSIONS: More research is re-
quired to better understand adverse events and side effects of ovarian cancer treat-
ments. This study suggests that sodium chloride and dextrose were the most fre-
quently prescribed drugs after diagnosis of ovarian cancer.
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